Global Blood Cancer Drug Market, By Type (Leukaemia, Lymphoma, Myeloma), Treatment (Medication, Radiation Therapy, Stem Cell Transplant, Others), Diagnosis (Blood Tests, Bone Marrow Biopsy, Urine Tests, Imaging Tests), Dosage Forms (Capsule, Tablets, Injections, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Blood Cancer Drug Market Analysis and Size
According to a survey by Bristol-Myers Squibb, approximately 1.85 million new cases of blood cancer drug will be diagnosed worldwide in 2040, with 918,872 cases of lymphoma, 656,345 cases of leukaemia, and 275,047 cases of myeloma. Furthermore, the survey predicted that by 2040, there will be around 1,100,000 fatalities worldwide owing to blood cancer drug. Cancer that starts in blood-forming tissue, such as bone marrow, or in immune system cells. Leukemia, lymphoma, and multiple myeloma are examples of blood cancer drugs. Hematologic cancer is another name for it. Drugs including bosulif, busulfan, bosutinib and busulfex are used to treat blood cancer drug.
Data Bridge Market Research analyses that the global blood cancer drug market which was USD 47.47 million in 2022, is expected to reach USD 98.29 million by 2030, and is expected to undergo a CAGR of 9.6% during the forecast period. This indicates that the market value. “Hospitals” dominates the end-users segment of the blood cancer drug market owing to rise in the prevalence of brain injury. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Blood Cancer Drug Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Leukaemia, Lymphoma, Myeloma), Treatment (Medication, Radiation Therapy, Stem Cell Transplant, Others), Diagnosis (Blood Tests, Bone Marrow Biopsy, Urine Tests, Imaging Tests), Dosage Forms (Capsule, Tablets, Injections, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Merck KGaA (Germany), LEO Pharma A/S (Denmark), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Fresenius Kabi AG (Germany), Amneal Pharmaceuticals LLC. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Most blood cancer drugs, also known as hematologic malignancies, begin in the bone marrow, which produces blood. When aberrant blood cells develop out of control, they disrupt the function of normal blood cells, which fight infection and make new blood cells. Commercially available chemotherapeutic drugs for the treatment of blood cancer drug include Leukeran, Oncotrex, Cytarine, Neosar, Gleevec, and others. Anticancer medicines are used in chemotherapy which functions by inhibiting the growth of cancer cells in the body. Chemotherapy for blood cancer drug may include administering numerous medications in a specific order. This treatment can also be used in conjunction with a stem cell transplant. Radiation therapy can be used to fight cancer and relieve pain and discomfort.
Blood Cancer Drug Market Dynamics
Drivers
- Introduction of Monoclonal Antibodies with Safety Profile to Fight Myeloma Cells
The expansion of the blood cancer drug market is fueled by the increasing use of microRNA treatments, the rise of nanomedicine platforms, and the constant introduction of effective and safe therapeutics. With the addition of monoclonal antibodies and histone deacetylase (HDAC) inhibitors to the present therapies array, the medicines market is likely to gain traction. Because of the established clinical profile, clinicians favour biologic therapy with monoclonal antibodies such as darzalex and empliciti.
- Increasing Prevalence of Blood Cancer Drug
The rising prevalence of blood cancer drug is estimated to enhance the blood cancer drug market's growth rate. Blood cancer drug is a form of hematological cancer triggered by certain genetic defects. The disease is treated with medications that modify the immune system and assist in improving the efficacy of chemotherapies, radiation therapies, stem cell transplants, and platelet transfusions
Opportunity
- Increase in the Number of Research and Development Activities
The blood cancer drug market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the blood cancer drug market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate. The introduction of monoclonal antibodies (mAbs) (including Empliciti and Darzalex) will act as major opportunity for market's growth, as they will not only provide a new therapeutic option for blood cancer drug patients, but they will also extend the time between relapses, extending the duration of Revlimid and Velcade therapies. Ninlaro and Kyprolis, two second-generation proteasome inhibitors, will also be available to these patients, expanding their therapy options. This will have an impact on the industry and market, which is now controlled by Revlimid, an immunomodulator, and Velcade, a proteasome inhibitor
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the blood cancer drug market growth during the forecast period
Restraint/Challenge
- Low Treatment Rates in Developing Countries
On the other hand, low treatment rates in developing countries because of the high cost associated with the treatment of blood cancer drug will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the blood cancer drug market. In addition, a decline in clinical visits due to COVID-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2023 to 2030
This blood cancer drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the blood cancer drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth
Recent Development
- In April 2021, U.S. Food and Drug Administration (FDA) had announced the approval of BCMA-targeted CAR T-Cell Therapy for the treatment of blood cancer drug. The current approval is based in part on the findings of a small research that found that idecabtagene vicleucel (ide-cel) reduced tumor size in 72 percent of patients. These effects persisted on average 11 months
- In June 2021, AbbVie acquired the TeneoOne and its key immunotherapeutic asset for treating blood cancer drug named TNB-383B. TNB-383B is a bispecific antibody that targets both BCMA and CD3 and is designed to direct the body's own immune system to target and kill BCMA-expressing tumor cells. AbbVie and TeneoOne announced a strategic partnership in February 2019 to develop and commercialize TNB-383B, a bispecific antibody that targets both BCMA and CD3 and is designed to direct the body's own immune system to target and kill BCMA-expressing tumor cells. Based on an interim review of an ongoing Phase I research, AbbVie exercised its acquisition right
Global Blood Cancer Drug Market Scope
Global blood cancer drug market is segmented on the basis of type, treatment, diagnosis, dosage forms, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Leukaemia
- Lymphoma
- Myeloma
Treatment
- Medications
- Proteasome Inhibitors
- Bortezomib
- Ixazomib
- Carfilzomib
- Histone Deacetylase (HDAC) Inhibitors
- Chemotherapy Drugs
- Bendamustine
- Etoposide
- Doxorubicin
- Liposomal Doxorubicin
- Cyclophosphamide
- Melphalan
- Vincristine
- Immunotherapy Drugs
- Lenalidomide
- Thalidomide
- Pomalidomide
- Corticosteroids
- Dexamethasone
- Prednisone
- Monoclonal antibodies
- Daratumumab
- Isatuximab
- Elotuzumab
- Radiation Therapy
- Stem Cell Transplant
- Others
Diagnosis
- Blood Tests
- Bone Marrow Biopsy
- Urine Tests
- Imaging Tests
- X-ray
- Magnetic resonance imaging (MRI)
- Positron Emission Tomography (PET)
Dosage Forms
- Capsule
- Tablets
- Injections
- Others
Route of Administration
- Oral
- Parenteral
- Intravenous
- Others
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Blood Cancer Drug Market Regional Analysis/Insights
The blood cancer drug market is analysed and market size insights and trends are provided by type, treatment, diagnosis, dosage forms, route of administration, end-users and distribution channel as referenced above.
The countries covered in the blood cancer drug market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the blood cancer drug market because of the growing prevalence of blood cancer drug and the rising geriatric population. In addition, growing demand for biologic therapies and people's unhealthy lifestyle will further propel the market’s growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to the increasing penetration of novel cancer drugs and rising healthcare expenditure. Also, growing government initiatives will further cushion the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Blood Cancer Drug Market Share Analysis
The blood cancer drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to blood cancer drug market.
Some of the major players operating in the blood cancer drug market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- AstraZeneca (U.K.)
- AbbVie Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- Merck KGaA (Germany)
- LEO Pharma A/S (Denmark)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Fresenius Kabi AG (Germany)
- Amneal Pharmaceuticals LLC. (U.S.)
SKU-